Biovista Awarded Research Grant on Chronic Fatigue Syndrome From Solve ME/CFS Initiative

March 6, 2012Press Releases

CHARLOTTESVILLE, Virginia, March 6, 2012 /PRNewswire/ — Biovista announced today that it has been awarded a prestigious research grant by Solve ME/CFS Initiative to identify non-obvious mechanisms of the disease and potential drug repositioning candidates that will advance objective diagnosis and effective treatment of chronic fatigue syndrome (CFS). As part of its work, Biovista will share … Read More

Biovista Inc. Receives Prestigious EU Grant to use its Drug Repositioning Platform for Personalized Medicine

May 5, 2011Press Releases

CHARLOTTESVILLE, Virginia and ATHENS, Greece, May 5, 2011 /PRNewswire/ — Biovista Inc. announced today that it’s EU affiliate has been awarded a prestigious grant worth $0.5 million, for research and development in the area of personalized medicine. The “p-medicine” project is a four-year, 13.3 million Euro co-funded effort under the European Community’s 7th Framework Programme … Read More

Biovista Announces Research Collaboration With a Major Pharmaceutical Company

April 27, 2011Press Releases

CHARLOTTESVILLE, Virginia, April 27, 2011 /PRNewswire/ — Biovista announced today that it has entered into a research collaboration agreement with Novartis. The collaboration is focused on identifying new indications for a number of undisclosed Novartis compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. The terms of the agreement include an upfront payment and success-based … Read More

Biovista Announces a Drug Repositioning Collaboration With Pfizer

November 9, 2010Press Releases

CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ — Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista’s Clinical Outcome Search Space (COSS) technology. Under the terms … Read More